Drug Trial News

RSS

Hyperuricemia associated with more severe hepatic ATP depletion in response to fructose intake

Obese patients with type 2 diabetes who consume higher amounts of fructose display reduced levels of liver adenosine triphosphate (ATP)—a compound involved in the energy transfer between cells.

14 Sep 2012

Emmaus Medical to complete target enrollment in L-Glutamine Phase III trial for sickle cell disease

In conjunction with Sickle Cell Awareness Month, Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine technology company, announced that its U.S. Phase III clinical trial to study L-Glutamine as a treatment for sickle cell disease is nearing target enrollment completion, with investigation now underway at more than 30 clinical study sites throughout the U.S.

14 Sep 2012

Senesco initiates SNS01-T cohort 2 trial in multiple myeloma

Senesco Technologies, Inc. reported today that the first patient has been enrolled and dosing has been initiated in cohort 2 of its clinical trial with SNS01-T in multiple myeloma.

14 Sep 2012

Biodel initiates BIOD-123 Phase 2 trial in Type 1 diabetes

Biodel Inc. today announced the initiation of a Phase 2 clinical trial of its proprietary recombinant insulin (RHI)-based ultra-rapid-acting mealtime insulin candidate, BIOD-123.

13 Sep 2012

Positive results from Edison’s EPI-743 phase 2A study on Leigh Syndrome

Edison Pharmaceuticals today announced positive results of a recently completed phase 2A study entitled, "Prospective Open Label Study of EPI-743 in Children with Leigh Syndrome (Subacute Necrotizing Encephalomyelopathy)."

13 Sep 2012

Glenmark's GBR 500 enters Phase II clinical development for severe ulcerative colitis

Glenmark Pharmaceuticals S.A. (GPSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals Limited (GPL), announced today that GBR 500 has entered Phase II clinical development.

13 Sep 2012

Positive data from Tetraphase Pharmaceuticals’ eravacycline Phase 2 trial on cIAI

Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing novel antibiotics effective against antibiotic-resistant bacteria, presented new, positive Phase 2 clinical data on its lead drug candidate, eravacycline (TP-434), on September 11, 2012, at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.

13 Sep 2012

Data from Oncolytics’ REOLYSIN Phase III combination trial on head and neck cancers

Oncolytics Biotech Inc. today provided an update on its Phase III trial of REOLYSIN in combination with carboplatin and paclitaxel for the treatment of head and neck cancers (REO 018).

12 Sep 2012

Transcept completes enrollment in TO-2061 Phase 2 trial for obsessive compulsive disorder

Transcept Pharmaceuticals, Inc. today announced that it has completed enrollment in its Phase 2 clinical trial evaluating TO-2061 added as adjunctive therapy for patients with obsessive compulsive disorder (OCD) who have not adequately responded to first-line treatment with an approved OCD medication.

12 Sep 2012

MD Anderson joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that MD Anderson Cancer Center in Houston, Texas has joined the Company's ongoing Phase I/II trial in newly diagnosed patients with acute myeloid leukemia (AML).

12 Sep 2012

Gene therapy regimen can safely restore immune systems to children with Bubble Boy disease

UCLA stem cell researchers have found that a gene therapy regimen can safely restore immune systems to children with so-called "Bubble Boy" disease, a life threatening condition that if left untreated can be fatal within one to two years.

12 Sep 2012

Leading dengue fever vaccine candidate 30% effective in first large clinical trial

"The leading candidate to become the world's first vaccine against dengue fever was only 30 percent effective in its first large clinical trial, dealing at least a temporary setback to efforts to control a disease that threatens half the world's population," the New York Times reports.

12 Sep 2012

Daily low-dose inhaled corticosteroids do not benefit asthmatics

For two decades, asthma treatment for millions of people with a milder form of the disease has consisted of daily inhaled steroid medicine to reduce inflammation. Now, a new study has found that asthmatics who take the low-dose medication as a daily routine do no better than those who turn to their inhalers only when they have symptoms.

12 Sep 2012

Researchers present new results from RV144 HIV vaccine trial at AIDS Vaccine 2012

"A paper published in Nature on Monday sheds light on how a vaccine can turn the immune system against [HIV] and so offer protection from infection," Nature News reports, noting "[t]he results are also being presented at the AIDS Vaccine 2012 conference in Boston, Massachusetts, this week."

12 Sep 2012

e-Therapeutics initiates second ETS2101 phase I trial in solid tumours

e-Therapeutics plc announces that it has started a second phase I clinical trial of its anti-cancer drug ETS2101. This trial will enrol up to 45 patients with a variety of solid tumours at two UK centres, St James's University Hospital in Leeds and the Northern Centre for Cancer Care at the Freeman Hospital in Newcastle.

12 Sep 2012

KaloBios commences KB003 Phase 2 trial in severe asthma

KaloBios Pharmaceuticals, Inc. today announced that dosing has begun in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of KB003, the company's anti-GM-CSF Humaneered monoclonal antibody, in subjects with severe asthma uncontrolled by corticosteroids.

12 Sep 2012

Ginkgo biloba supplements fail to improve cognitive performance in multiple sclerosis

A research study conducted by Dr. Jesus Lovera, Assistant Professor of Neurology at LSU Health Sciences Center New Orleans, and colleagues has found that the herbal supplement Ginkgo biloba does not improve cognitive function in patients with Multiple Sclerosis (MS).

12 Sep 2012

Positive results from Santarus rifamycin SV MMX Phase III study on travelers' diarrhea

Santarus, Inc. today announced that its Phase III clinical study to evaluate the safety and efficacy of the investigational drug, rifamycin SV MMX, met the primary endpoint of reducing time to last unformed stool (TLUS) in patients with travelers' diarrhea.

12 Sep 2012

GE Healthcare announces data from [18F]flutemetamol phase III studies on Alzheimer's

GE Healthcare today announced pooled results from phase III brain autopsy and biopsy studies on the investigational PET amyloid imaging agent, [18F]flutemetamol, which showed a strong concordance between [18F]flutemetamol images and Alzheimer's disease-associated beta amyloid brain pathology.

11 Sep 2012

Durata Therapeutics completes dalbavancin Phase 3 trials on ABSSSI

Durata Therapeutics today announced results from its QT study of the company's lead product candidate, dalbavancin. Dalbavancin is currently under investigation in two ongoing, global, Phase 3 clinical trials for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

11 Sep 2012

Drug Trial News

Hyperuricemia associated with more severe hepatic ATP depletion in response to fructose intake

Emmaus Medical to complete target enrollment in L-Glutamine Phase III trial for sickle cell disease

Senesco initiates SNS01-T cohort 2 trial in multiple myeloma

Biodel initiates BIOD-123 Phase 2 trial in Type 1 diabetes

Positive results from Edison’s EPI-743 phase 2A study on Leigh Syndrome

Glenmark's GBR 500 enters Phase II clinical development for severe ulcerative colitis

Positive data from Tetraphase Pharmaceuticals’ eravacycline Phase 2 trial on cIAI

Data from Oncolytics’ REOLYSIN Phase III combination trial on head and neck cancers

Transcept completes enrollment in TO-2061 Phase 2 trial for obsessive compulsive disorder

MD Anderson joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Gene therapy regimen can safely restore immune systems to children with Bubble Boy disease

Leading dengue fever vaccine candidate 30% effective in first large clinical trial

Daily low-dose inhaled corticosteroids do not benefit asthmatics

Researchers present new results from RV144 HIV vaccine trial at AIDS Vaccine 2012

e-Therapeutics initiates second ETS2101 phase I trial in solid tumours

KaloBios commences KB003 Phase 2 trial in severe asthma

Ginkgo biloba supplements fail to improve cognitive performance in multiple sclerosis

Positive results from Santarus rifamycin SV MMX Phase III study on travelers' diarrhea

GE Healthcare announces data from [18F]flutemetamol phase III studies on Alzheimer's

Durata Therapeutics completes dalbavancin Phase 3 trials on ABSSSI

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News